← boardnext 2026-09-30next 2027-09
CHRS
Coherus Oncology, Inc.distress 7/10 · high distress / dilution risk$1.42-1%today-44% from 52w high
Oncology 2
Lead: Advanced Solid Tumor · target PD-L1
Revenue
pre-revenue
Liquidity
$167M
Runway
1.0 yrs
Shares 1y
+33%
Price & events
-11.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
+1.8%
1W
-3.1%
1M
-19.6%
3M
-31.3%
6M
+44.5%
1Y
-14.8%
2Y
-89.2%
5Y
-91.6%
All
Overview
- Market Cap
- $218.26M
- Volume
- 91.11K
- 52 Week Range
- $0.82 – $2.51
- Total Shares
- 154.25M
- Float Shares
- 135.35M
- Short %
- 17.35%
- % Held by Insiders
- 18.66%
- % Held by Institutions
- 38.65%
- RVOL
- 0.10x
- Beta
- 0.98
Pipeline stages · 3 programs
CHS-1000, Toripalimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Casdozokitug, Toripalimab, Bevacizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
SRF388, Atezolizumab, BevacizumabPD-L1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-10-30 | Phase 1 | CHS-114, toripalimab | Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | Casdozokitug, Toripalimab, Bevacizumab | Hepatocellular Carcinoma | — | active not recruiting |
| 2028-01 Estimated 50% readout ~2028-01-31 | Phase 1 | CHS-114, Toripalimab, 5 Fluorouracil | Metastatic Solid Tumor, Advanced Solid Tumor | — | recruiting |
| 2028-05-30 Estimated 50% readout ~2028-06-29 | Phase 1 | CHS-1000, Toripalimab | Advanced or Metastatic Solid Tumors | — | not yet recruiting |
| 2025-06-30 | Phase 2 | SRF388, Atezolizumab, Bevacizumab | Hepatocellular Carcinoma | 30 | completed |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-05-28 | Phase 1 | CHS-388, Pembrolizumab, Toripalimab | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer | 145 | completed |
Catalyst news & presentations · 6
- 2026Guided 40%readoutKey data readouts expected in 2026SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-02-04partnershiptagmokitug (CHS-114), pasritamig · Clinical supply agreement with Janssen for Phase 1b combination trial in mCRPC.SEC 8-K
- April 15, 2025enrollment completesecondaryRepurchase of convertible notes expected to close on April 15, 2025.SEC 8-K
- 2025-04-11partnershipUDENYCA · Completed divestiture of UDENYCA franchise to Intas for $483.4M upfront with potential $75M milestones.SEC 8-K
- 2024-12-02partnershipUDENYCA (pegfilgrastim-cbqv) · Asset purchase agreement with Intas Pharmaceuticals for $483.4M cash plus milestones.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $8 (+451% upside) · 5 analysts
- 2026-05-11GuggenheimBuy
- 2026-01-22OppenheimerOutperform
- 2025-09-04Maxim GroupHold → Buy
- 2025-04-29HC Wainwright & Co.Buy
- 2025-04-24UBSNeutral
- 2025-03-11HC Wainwright & Co.Buy
Competitors — PD-L1
Recent news
- 2026-07-22Coherus Oncology to report Q2 2026 financial results on August 5 - scanx.trade
- 2026-07-22Coherus Oncology Announces Date for Second Quarter 2026 Financial Results Conference Call and Webcast - Quiver Quantitative
- 2026-07-22Coherus to webcast second-quarter results Aug. 5 at 5 p.m. - Stock Titan
- 2026-07-22Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - GlobeNewswire
- 2026-07-22Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 - GlobeNewswire
- 2026-07-21Q3 2025 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
- 2026-07-08Coherus Oncology (CHRS) H.C. Wainwright 27th Annual Global Investment Conference summary - Quartr
- 2026-07-08CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock Reaction - Dividend Earnings Report - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.